Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Viatris Inc. or Teva Pharmaceutical Industries Limited because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Viatris Inc. and Teva Pharmaceutical Industries Limited compare based on key financial metrics to determine which better meets your investment needs.

About Viatris Inc. and Teva Pharmaceutical Industries Limited

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Latest Pharmaceuticals and Viatris Inc., Teva Pharmaceutical Industries Limited Stock News

As of September 1, 2026, Viatris Inc. had a $19.1 billion market capitalization, compared to the Pharmaceuticals median of $654.2 million. Viatris Inc.’s stock is up 37.3% in 2026, up 1.5% in the previous five trading days and up 57.63% in the past year.

Currently, Viatris Inc. does not have a price-earnings ratio. Viatris Inc.’s trailing 12-month revenue is $14.7 billion with a -2.8% net profit margin. Year-over-year quarterly sales growth most recently was 4.9%. Analysts expect adjusted earnings to reach $2.501 per share for the current fiscal year. Viatris Inc. currently has a 2.9% dividend yield.

As of September 1, 2026, Teva Pharmaceutical Industries Limited had a $42.2 billion market cap, putting it in the 92nd percentile of all stocks. Teva Pharmaceutical Industries Limited’s stock is up 20% in 2026, down 1.2% in the previous five trading days and up 96.9% in the past year.

Currently, Teva Pharmaceutical Industries Limited’s price-earnings ratio is 60.1. Teva Pharmaceutical Industries Limited’s trailing 12-month revenue is $17.3 billion with a 4.1% net profit margin. Year-over-year quarterly sales growth most recently was -0.8%. Analysts expect adjusted earnings to reach $2.143 per share for the current fiscal year. Teva Pharmaceutical Industries Limited does not currently pay a dividend.

How We Compare Viatris Inc. and Teva Pharmaceutical Industries Limited Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Viatris Inc. and Teva Pharmaceutical Industries Limited’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Viatris Inc. and Teva Pharmaceutical Industries Limited Growth Grades

Company	Ticker	Growth
Viatris Inc.	VTRS	D
Teva Pharmaceutical Industries Limited	TEVA	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Viatris Inc. has a Growth Score of 32, which is Weak. Teva Pharmaceutical Industries Limited has a Growth Score of 35, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Viatris Inc. or Teva Pharmaceutical Industries Limited has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Viatris Inc. or Teva Pharmaceutical Industries Limited is the better investment when it comes to sustainable growth.

Viatris Inc. and Teva Pharmaceutical Industries Limited’s Momentum Grades

Company	Ticker	Momentum
Viatris Inc.	VTRS	B
Teva Pharmaceutical Industries Limited	TEVA	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Viatris Inc. has a Momentum Score of 77, which is Strong. Teva Pharmaceutical Industries Limited has a Momentum Score of 86, which is Very Strong.

The Momentum Grade Winner: Teva Pharmaceutical Industries Limited

As you can clearly see from the Momentum Grade breakdown above, Teva Pharmaceutical Industries Limited is considered to have stronger momentum compared to Viatris Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Teva Pharmaceutical Industries Limited could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Viatris Inc. and Teva Pharmaceutical Industries Limited’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Viatris Inc.	VTRS	B
Teva Pharmaceutical Industries Limited	TEVA	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Viatris Inc. has a Earnings Estimate Score of 73, which is Positive. Teva Pharmaceutical Industries Limited has a Earnings Estimate Score of 36, which is Negative.

The Earnings Estimate Revisions Grade Winner: Viatris Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Viatris Inc. has a better Earnings Estimate Revisions Grade than Teva Pharmaceutical Industries Limited. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Viatris Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Viatris Inc. and Teva Pharmaceutical Industries Limited Grades

In addition to Momentum, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Viatris Inc. and Teva Pharmaceutical Industries Limited pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Viatris Inc. or Teva Pharmaceutical Industries Limited Stock?

Overall, Viatris Inc. stock has a Growth Score of 32, Momentum Score of 77 and Estimate Revisions Score of 73.

Teva Pharmaceutical Industries Limited stock has a Growth Score of 35, Momentum Score of 86 and Estimate Revisions Score of 36.

Comparing Viatris Inc. and Teva Pharmaceutical Industries Limited’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.